Table 4:

Factors associated with development of HCC in patients with LR-3 or LR-4 observations.

Author Year	Patient-level factors	Observation-level factors
Tang 2019	Age, per 10-year increase (OR 1.76, 95%CI 1.00–3.07)	Diameter >2cm (OR 21.69, 95% CI 5.36–87.74) Delayed washout (OR 5.34, 95% CI 1.90–15.03)
Ojeda 2021	Male sex (HR: 4.27, 95% CI 1.75-9.27) Age, per 10-year increase (HR: 1.49, 95% CI 1.03-1.91)
Sofue 2017	Hepatitis C etiology (HR 1.69, 95%CI 1.07–2.75)	Threshold growth (HR 3.71, 95% CI 1.51–8.75) Mild-to-moderate T2 hyperintensity (HR 1.84, 95% CI 1.22–2.76)
Hong 2019	Follow-up duration, per year (OR = 1.77, 95%CI 1.06-2.95)
Arvind 2022	Age >60 years (HR 1.82, 95% CI 1.06-3.13) Male sex (HR 1.83, 95% CI 1.02-3.30) AFP >10 ng/mL (HR 3.11, 95% CI 1.80-5.36)	LR-3 diameter ≥1.0 cm (HR 1.86; 95%CI 1.05-3.31)
Agnello 2020		LR3: diameter ≥ 1 cm (OR 6.07; 95%CI 0.12-60.28) LR4: diameter ≥ 1 cm (OR 8.95, 95%CI 0.73 – 111.8)
Smereka 2020	Viral liver disease etiology (p = 0.01) Presence of HCC (p = 0.02) LI-RADS v2017 vs. 2018 (p=0.04)	Mild-to-moderate T2 hyperintensity (p<0.001)
Tang 2017	Male sex Liver disease etiology	LI-RADS major features (arterial phase hyperenhancement, delayed washout, presence of pseudocapsule) Interval growth Lesions visible on US